The potential of SERMs for reducing the risk of coronary heart disease

Trends in Endocrinology and Metabolism

Volumn 10, Issue 8, 1999, Pages 320-325

  Barrett Connor, Elizabeth ^a   Cox, David A ^b   Anderson, Pamela W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000048965     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(99)00182-4     Document Type: Review

References (11)

1. Wenger, N.K. (1997) Coronary heart disease: an older woman's major health risk. Br. Med. J. 315, 1085-1090
2. Barrett-Connor, E. and Grady, D. (1998) Hormone replacement therapy, heart disease and other considerations. Annu. Rev. Public Health 19, 55-72
3. Hulley, S. et al. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280, 605-613
4. Woodruff, J.D. and Pickar, J.H. (1994) Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The menopause study group. Am. J. Obstet. Gynecol. 170, 1213-1223
5. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors hi postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J. Am. Med. Assoc. 273, 199-208
6. Adams, M.R., Register, T.C., Golden, D.L., Wagner, J.D. and Williams, J.K. (1997) Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17, 217-274
7. Sorenson, K.E., Dorup, I., Hermann, A.P. and Mosekilde, L. (1998) Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 97, 1234-1238
8. The Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J. Am. Med. Assoc. 276, 1389-1396
9. Cauley, J.A., Seeley, D.G., Ensrud, K., Ettinger, B., Black, D. and Cummings, S.R. (1995) Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann. Intern. Med. 122, 9-16
10. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V. and Petitti, D. (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85, 304-313
11. Beresford, S.A., Weiss, N.S., Voigt, L.F. and McKnight, B.S. (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349, 458-461